BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, Bouros D, Glassberg MK. Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2018;5:142. [PMID: 29868594 DOI: 10.3389/fmed.2018.00142] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Ikonomou L, Wagner DE, Turner L, Weiss DJ. Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases. Ann Am Thorac Soc 2019;16:657-68. [PMID: 30917290 DOI: 10.1513/AnnalsATS.201812-890CME] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
2 McClain Caldwell I, Hogden C, Nemeth K, Boyajian M, Krepuska M, Szombath G, MacDonald S, Abshari M, Moss J, Vitale-Cross L, Fontana JR, Mezey E. Bone Marrow-Derived Mesenchymal Stromal Cells (MSCs) Modulate the Inflammatory Character of Alveolar Macrophages from Sarcoidosis Patients. J Clin Med 2020;9:E278. [PMID: 31963936 DOI: 10.3390/jcm9010278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Jiang R, Liao Y, Yang F, Cheng Y, Dai X, Chao J. SPIO nanoparticle-labeled bone marrow mesenchymal stem cells inhibit pulmonary EndoMT induced by SiO2. Exp Cell Res 2019;383:111492. [PMID: 31291564 DOI: 10.1016/j.yexcr.2019.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Becerra J, Duran I. Inflammation, a common mechanism in frailty and COVID19, and stem cells as a therapeutic approach. Stem Cells Transl Med 2021. [PMID: 34164948 DOI: 10.1002/sctm.21-0074] [Reference Citation Analysis]
5 Shi L, Ren J, Li J, Wang D, Wang Y, Qin T, Li X, Zhang G, Li C, Wang Y. Extracellular vesicles derived from umbilical cord mesenchymal stromal cells alleviate pulmonary fibrosis by means of transforming growth factor-β signaling inhibition. Stem Cell Res Ther 2021;12:230. [PMID: 33845892 DOI: 10.1186/s13287-021-02296-8] [Reference Citation Analysis]
6 van Geffen C, Deißler A, Quante M, Renz H, Hartl D, Kolahian S. Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes? Front Immunol 2021;12:663203. [PMID: 33995390 DOI: 10.3389/fimmu.2021.663203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rolandsson Enes S, Weiss DJ. Cell Therapy for Lung Disease: Current Status and Future Prospects. Curr Stem Cell Rep 2020;6:30-9. [DOI: 10.1007/s40778-020-00171-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Atanasova E, Milosevic D, Bornschlegl S, Krucker KP, Jacob EK, Carmona Porquera EM, Anderson DK, Egan AM, Limper AH, Dietz AB. Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients. Stem Cell Res Ther 2022;13. [DOI: 10.1186/s13287-021-02692-0] [Reference Citation Analysis]
9 Adamcakova J, Mokra D. New Insights into Pathomechanisms and Treatment Possibilities for Lung Silicosis. Int J Mol Sci 2021;22:4162. [PMID: 33920534 DOI: 10.3390/ijms22084162] [Reference Citation Analysis]
10 Behnke J, Kremer S, Shahzad T, Chao CM, Böttcher-Friebertshäuser E, Morty RE, Bellusci S, Ehrhardt H. MSC Based Therapies-New Perspectives for the Injured Lung. J Clin Med 2020;9:E682. [PMID: 32138309 DOI: 10.3390/jcm9030682] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 25.5] [Reference Citation Analysis]
11 Lu Q, El-Hashash AHK. Cell-based therapy for idiopathic pulmonary fibrosis. Stem Cell Investig 2019;6:22. [PMID: 31559309 DOI: 10.21037/sci.2019.06.09] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
12 Antoniou KM, Tsitoura E, Vasarmidi E, Symvoulakis EK, Aidinis V, Tzilas V, Tzouvelekis A, Bouros D. Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. Curr Opin Pharmacol 2021;57:71-80. [PMID: 33556824 DOI: 10.1016/j.coph.2020.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Gad ES, Salama AAA, El-Shafie MF, Arafa HMM, Abdelsalam RM, Khattab M. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats. Inflammation 2020;43:123-34. [PMID: 31646446 DOI: 10.1007/s10753-019-01101-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
14 Shi L, Han Q, Hong Y, Li W, Gong G, Cui J, Mao M, Liang X, Hu B, Li X, Luo Q, Zhang Y. Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis. Stem Cell Res Ther 2021;12:147. [PMID: 33632305 DOI: 10.1186/s13287-021-02215-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Barkama R, Mayo A, Paz A, Solopov A, Mann T, Vadasz Z, Appel T, Ofir R, Shani L, Sheleg M, Allen H, Shaked Nitzan R, Tsarfaty N, Gilad H, Birch T, Kachel E, Reinke P, Volk HD, Zalts R, Raz Pasteur A. Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. Crit Care Explor 2020;2:e0207. [PMID: 32984833 DOI: 10.1097/CCE.0000000000000207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Chen L, Qu J, Kalyani FS, Zhang Q, Fan L, Fang Y, Li Y, Xiang C. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04096-y] [Reference Citation Analysis]
17 Tzouvelekis A, Karampitsakos T, Bouros E, Tzilas V, Liossis S, Bouros D. Autoimmune Biomarkers, Antibodies, and Immunologic Evaluation of the Patient with Fibrotic Lung Disease. Clinics in Chest Medicine 2019;40:679-91. [DOI: 10.1016/j.ccm.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives. Stem Cells Int. 2019;2019:4236973. [PMID: 31191672 DOI: 10.1155/2019/4236973] [Cited by in Crossref: 54] [Cited by in F6Publishing: 70] [Article Influence: 18.0] [Reference Citation Analysis]
19 Karina K, Christoffel LM, Novariani R, Rosadi I, Rosliana I, Rosidah S, Sobariah S, Fatkhurohman N, Puspitaningrum N, Hertati Y, Afini I, Ernanda D, Widyastuti T, Sulaeha AD, Zakiyah A, Aini N, Krisandi G, Andrew H. The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on "Profibrotic Cytokine" IL-1β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study. Scientifica (Cairo) 2021;2021:9427978. [PMID: 34306796 DOI: 10.1155/2021/9427978] [Reference Citation Analysis]
20 Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM, Caplan AI, Kurtzberg J, Zubair AC, Kubrova E, Engelberg-Cook E, Nayfeh T, Shah VP, Hill JC, Wolf ME, Prokop LJ, Murad MH, Sanfilippo FP. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9:1007-1022. [PMID: 32472653 DOI: 10.1002/sctm.20-0146] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
21 Patete CL, Toonkel RL, Glassberg M. Stem Cell Based Therapy for Lung Disease Preclinical evidence for the role of stem/stromal cells Clinical application of stem/stromal cells in lung fibrosis. In: Burgess JK, Heijink IH, editors. Stem Cell-Based Therapy for Lung Disease. Cham: Springer International Publishing; 2019. pp. 119-30. [DOI: 10.1007/978-3-030-29403-8_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Filidou E, Kandilogiannakis L, Tarapatzi G, Spathakis M, Steiropoulos P, Mikroulis D, Arvanitidis K, Paspaliaris V, Kolios G. Anti-Inflammatory and Anti-Fibrotic Effect of Immortalized Mesenchymal-Stem-Cell-Derived Conditioned Medium on Human Lung Myofibroblasts and Epithelial Cells. Int J Mol Sci 2022;23:4570. [PMID: 35562961 DOI: 10.3390/ijms23094570] [Reference Citation Analysis]
23 Zavvar M, Yahyapoor A, Baghdadi H, Zargaran S, Assadiasl S, Abdolmohammadi K, Hossein Abooei A, Reza Sattarian M, Jalalifarahani M, Zarei N, Farahvash A, Fatahi Y, Deniz G, Zarebavani M, Nicknam MH. COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches. International Immunopharmacology 2022;107:108655. [DOI: 10.1016/j.intimp.2022.108655] [Reference Citation Analysis]
24 Gao Y, Raj JU. Extracellular Vesicles as Unique Signaling Messengers: Role in Lung Diseases. Compr Physiol 2020;11:1351-69. [PMID: 33294981 DOI: 10.1002/cphy.c200006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Yang J, Hu H, Zhang S, Jiang L, Cheng Y, Xie H, Wang X, Jiang J, Wang H, Zhang Q. [Human umbilical cord mesenchymal stem cell-derived exosomes alleviate pulmonary fibrosis in mice by inhibiting epithelial-mesenchymal transition]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:988-94. [PMID: 32895166 DOI: 10.12122/j.issn.1673-4254.2020.07.11] [Reference Citation Analysis]
26 Guo Y, Wang L, Gou R, Wang Y, Shi X, Pang X, Tang L. SIRT1-modified human umbilical cord mesenchymal stem cells ameliorate experimental peritoneal fibrosis by inhibiting the TGF-β/Smad3 pathway. Stem Cell Res Ther 2020;11:362. [PMID: 32811535 DOI: 10.1186/s13287-020-01878-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Abdel Halim AS, Ahmed HH, Aglan HA, Abdel Hamid FF, Mohamed MR. Role of bone marrow-derived mesenchymal stem cells in alleviating pulmonary epithelium damage and extracellular matrix remodeling in a rat model of lung fibrosis induced by amiodarone. Biotech Histochem 2021;96:418-30. [PMID: 32909452 DOI: 10.1080/10520295.2020.1814966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Abreu H, Canciani E, Raineri D, Cappellano G, Rimondini L, Chiocchetti A. Extracellular Vesicles in Musculoskeletal Regeneration: Modulating the Therapy of the Future. Cells 2021;11:43. [PMID: 35011605 DOI: 10.3390/cells11010043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kolilekas L, Papiris S, Bouros D. Existing and emerging treatments for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine 2019;13:229-39. [DOI: 10.1080/17476348.2019.1568244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, Maher TM, Tzouvelekis A, Ryerson CJ. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacol Ther 2021;222:107798. [PMID: 33359599 DOI: 10.1016/j.pharmthera.2020.107798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]